Last updated: February 13, 2026
What is the Drug NDC 72578-0062?
NDC 72578-0062 is a drug product identified as Abecma (idecabtagene vicleucel), a CAR T-cell therapy approved by the FDA for multiple myeloma. It is a personalized treatment that involves genetic modification of a patient's T-cells to target cancer cells. The drug was approved on March 26, 2021. It was developed by Bristol-Myers Squibb (BMS) in collaboration with Celgene, now part of BMS.
How large is the market for Abecma?
The multiple myeloma market was valued at approximately $13.2 billion globally in 2022, with expected growth at a compound annual growth rate (CAGR) of approximately 8% through 2027[1].
Factors influencing the market include:
- Increasing incidence of multiple myeloma, estimated at 34,000 new cases annually in the US.
- Limitations of existing therapies, leading to high unmet medical needs.
- The exclusivity period granted by FDA through orphan drug designation, extending market protection until at least 2030.
- Growing adoption of CAR T-cell therapies in hematologic cancers.
What are the current pricing trends?
Pricing of CAR T-cell therapy generally
- The median list price for FDA-approved CAR T therapies ranges from $373,000 to $475,000 per patient[2].
- Real-world net prices tend to be lower due to rebates, negotiation, and insurance adjustments, typically around $300,000–$370,000.
Abecma-specific pricing
- The wholesale acquisition cost (WAC) for Abecma is listed at $425,000 per dose.
- The actual transaction price may vary based on partnerships, payer negotiations, and access programs.
Cost components
- The price includes manufacturing, clinical administration, and post-infusion management.
- Additional costs are tied to hospitalization and supportive care, potentially pushing the total treatment cost above $500,000 per patient.
How is the market expected to evolve?
Market penetration projections
- By 2030, annual sales for Abecma are projected to reach $1.2 billion to $1.5 billion in the U.S. alone.
- Global sales may surpass $2.5 billion, driven by expansion into Europe and Asia.
Factors impacting growth
- Expansion of indications: Clinical trials evaluating Abecma for earlier lines of therapy or other hematologic cancers are ongoing.
- Competitive landscape: Other CAR T therapies like Novartis's Kymriah and Gilead's Tecartus threaten market share but are aimed at different indications.
- Pricing pressures: Payers may negotiate discounts, especially as biosimilar and alternative therapies develop.
Regulatory and reimbursement considerations
- CMS and private insurers increasingly adopt value-based payment models.
- Medicare covers CAR T therapy under specific conditions, increasing access but exerting cost constraints.
What are the key risks and opportunities?
Risks
- Regulatory delays or safety concerns could impact market access.
- High manufacturing costs may constrain profit margins.
- Payer reimbursement policies could limit patient access.
Opportunities
- Potential for expanded indications, including earlier lines of therapy.
- New formulations or biosimilars could reduce costs.
- Partnerships with healthcare providers can facilitate wider adoption.
Price projections overview (2023–2027)
| Year |
Projected U.S. Sales |
Market Share |
Average Price per Treatment |
Notes |
| 2023 |
$300 million |
12% |
$425,000 |
Launch year, limited broader adoption |
| 2024 |
$600 million |
20% |
$426,000 |
Growing adoption in relapsed/Refractory MM |
| 2025 |
$1.0 billion |
28% |
$430,000 |
Expanded indications and increased access |
| 2026 |
$1.3 billion |
35% |
$435,000 |
Competition from newer therapies or biosimilars |
| 2027 |
$1.5 billion |
40% |
$440,000 |
Sustained growth in major markets |
These estimates assume continued market growth, moderate pricing adjustments, and expanding indication approvals.
Key Takeaways
- Abecma's high price reflects its personalized manufacturing process and novel therapeutic class.
- Market growth depends on indication expansion, regulatory environment, payer policies, and competitive dynamics.
- Pricing pressures are likely, with potential for discounts as the biosimilar market evolves.
- Estimated sales growth projects a significant increase through 2027, with annual revenues possibly exceeding $1.5 billion in the U.S.
- Access and reimbursement will significantly influence future market penetration and pricing stability.
FAQs
1. How does Abecma compare pricing-wise to other CAR T-cell therapies?
It is similarly priced to Novartis's Kymriah and Gilead's Tecartus, typically between $375,000 and $475,000 per treatment, with actual net prices lower after negotiations.
2. What factors could affect the future pricing of Abecma?
Emergence of biosimilars, new competition, changes in reimbursement policies, and manufacturing cost reductions could exert downward pressure.
3. What are the main therapeutic advantages of Abecma?
It targets relapsed/refractory multiple myeloma with a one-time infusion and demonstrated overall response rates around 73% in clinical trials.
4. How is market access facilitated for high-cost therapies like Abecma?
Through payer negotiations, risk-sharing agreements, patient assistance programs, and value-based contracting.
5. What markets offer the highest growth potential for Abecma?
The U.S. remains the largest, but Europe, Japan, and China are expanding due to increasing regulatory approvals and healthcare infrastructure developments.
References
[1] GlobalData, "Multiple Myeloma Market Analysis," 2022
[2] IQVIA, "Pharmaceutical Pricing Trends," 2022
